<SEC-DOCUMENT>0001610618-17-000033.txt : 20170510
<SEC-HEADER>0001610618-17-000033.hdr.sgml : 20170510
<ACCEPTANCE-DATETIME>20170510165529
ACCESSION NUMBER:		0001610618-17-000033
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170510
DATE AS OF CHANGE:		20170510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		17831262

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cdtx8-kq12017.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sACB2D54454655C52BCBCAED1CF3059F0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:313px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:313px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Date of Report (Date of earliest event reported): </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">May&#160;10, 2017</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:313px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">Cidara Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:313px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:3%;"></td><td style="width:31%;"></td><td style="width:3%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-36912</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">46-1537286</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(State or Other Jurisdiction of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6310 Nancy Ridge Drive, Suite 101</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">San Diego, California 92121</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858) 752-6170</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:313px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr></table></div><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).&#160; </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:162px;text-indent:-162px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Emerging growth company </font><font style="font-family:Wingdings;font-size:9pt;">x</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In this report, &#8220;Cidara Therapeutics,&#8221; &#8220;Cidara,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Cidara Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.02 Results of Operations and Financial Condition.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;10, 2017</font><font style="font-family:inherit;font-size:10pt;">, we issued a press release reporting our financial results for the </font><font style="font-family:inherit;font-size:10pt;">first</font><font style="font-family:inherit;font-size:10pt;">&#32;quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The full text of the press release is attached as exhibit 99.1 to this Current Report on Form 8-K.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with General Instruction B-2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit&#160;99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Exhibits</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release issued May 10, 2017, reporting financial results for the first quarter ended March 31, 2017.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:14px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:50%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cidara Therapeutics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 10, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jeffrey L. Stein</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey L. Stein</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:14px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO EXHIBITS</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release issued May 10, 2017, reporting financial results for the first quarter ended March 31, 2017.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51q2017earningsrelease_v12.htm
<DESCRIPTION>EARNINGS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFCCC270AD27DEFC52263D5BBA85634C3"></a></div><div><div style="line-height:166%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div></div><div><br></div><div style="line-height:166%;text-align:left;"><img src="cidara_finala03.jpg" alt="cidara_finala03.jpg" style="height:77px;width:208px;"></div><div style="line-height:166%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:166%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Cidara Provides Corporate Update and Reports First Quarter 2017 </font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Financial Results</font></div><div style="line-height:144%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SAN DIEGO, May 10, 2017</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8211; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and product pipeline.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;We are excited about the progress we are making on our CD101 IV and Cloudbreak&#8482; programs, which we discussed at our recent investor day,&#8221; said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. &#8220;We anticipate announcing topline data from our STRIVE Phase 2 trial of CD101 IV in the fourth quarter, and are advancing CD201 through IND-enabling studies. Our financial position remains strong, and I look forward to providing an update on our continued progress as the year unfolds.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Quarter 2017 and Subsequent Highlights</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Presented Data at ECCMID and SID Annual Meetings: </font><font style="font-family:inherit;font-size:12pt;">In April 2017, Cidara presented data from nonclinical studies of its novel echinocandin antifungal CD101 and its Cloudbreak antibacterial immunotherapy CD201 at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria, and at the 2017 Society for Investigative Dermatology (SID) Annual Meeting in Portland, Oregon.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:144%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Awarded Grant for up to $6.9 Million from CARB-X:</font><font style="font-family:inherit;font-size:12pt;">&#32;In March 2017, Cidara received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of its antibiotic immunotherapy, CD201, for the treatment of life-threatening multi-drug resistant (MDR) Gram-negative bacterial infections. CD201 is the first development candidate to be generated by Cidara&#8217;s novel Cloudbreak immunotherapy discovery platform, designed to create compounds that direct a patient&#8217;s immune cells to attack and eliminate bacterial, fungal or viral pathogens.</font></div></td></tr></table><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:144%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Quarter 2017 Financial Results</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cash, cash equivalents and short-term investments totaled $90.1 million as of March 31, 2017, compared with $104.6 million as of December 31, 2016. Management continues to expect cash burn of $60 to $65 million for 2017. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Research and development expenses were $10.2 million for the three months ended March 31, 2017, compared to $7.2 million for the same period in 2016. The increase was primarily attributable to clinical development activities for CD101.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">General and administrative expenses were $3.2 million for the three months ended March 31, 2017, compared to $2.7 million for the same period in 2016. The increase was primarily due to higher personnel-related costs to support the growth of operating activities.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Net loss for the three months ended March 31, 2017 was $13.4 million, compared to a net loss of $9.8 million for the first quarter of 2016. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As of April 30, 2017, Cidara had 16,806,042 common shares outstanding.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cidara Therapeutics</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients&#8217; lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins, and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara&#8217;s novel Cloudbreak&#8482; platform</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">and is designed to specifically direct a patient&#8217;s immune cells to attack and kill bacterial pathogens. Cidara recently received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, and other attributes of CD101 and CD201 and other potential product candidates, including the potential for these compounds to successfully treat or prevent fungal or bacterial infections, including those caused by resistant pathogens, and potentially transform the way infectious diseases are treated, and the potential for the Cloudbreak platform to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara&#8217;s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara&#8217;s plans to develop and commercialize its product candidates; Cidara&#8217;s ability to obtain additional financing; Cidara&#8217;s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara&#8217;s Form 10-K most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:166%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cidara Therapeutics, Inc.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:589px;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:344px;"></td><td style="width:6px;"></td><td style="width:105px;"></td><td style="width:4px;"></td><td style="width:13px;"></td><td style="width:6px;"></td><td style="width:105px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash, cash equivalents, and short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">104,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">779</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">106,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">75,989</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,179</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">106,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:166%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cidara Therapeutics, Inc.</font></div><div style="line-height:166%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Condensed Consolidated Statements of Operations</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.49572649572649%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(In thousands, except share and per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,696</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,398</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,885</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,398</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,885</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other income (expense):</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:9px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.71</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,795,366</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,807,825</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INVESTOR CONTACT:</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Robert H. Uhl</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Westwicke Partners, LLC</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Managing Director</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(858) 356-5932</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">robert.uhl@westwicke.com</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MEDIA CONTACT:</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Christy Curran</font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sam Brown Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(615) 414-8668</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ChristyCurran@sambrown.com</font></div><div style="line-height:144%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">###</font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cidara_finala03.jpg
<TEXT>
begin 644 cidara_finala03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #K G(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R_$WB3
M3O!^@WVLZM<K::=9QF6:5NP[ #N2<  =20*U*^8/V\-=N;/P7X<TJ)F2WOKV
M26;;_%Y:#:I]LR9^JCTKBQN(^JX>=:U['H9?A?KN*IX=NRD_PW9YI\0/VVO%
MNM:A*GA:.#P_IJL1%))"D]PX]6W H,^@''J:J>"?VUO'.AW\?]OFV\1V!.)$
M>%()@O\ L-& ,_53_6OGRBOS!YIC7/VGM7?\/NV/V)9-EZI^R]BK>FOW[_B?
MJSX&\;:5\1/#%EKVC3^?8W2Y 88>-APR..S \'],@@UOU\A?L#ZY<LWBW1F9
MFLU$%VB]D<[D8_B G_?-?7M?IF7XIXS#0K-:O?U6A^0YG@U@<7.A%W2V]'J%
M%%%>@>6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLY'F5:598:M+F3VONK:G@<1910A0>+H1Y7&U[;-/3;O<^J:***^\/S4****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *2EHH _+3XK>!;GX<_$#6M!N(F1+>=C;L1Q) QS&P^JD?0@CM7)5^
MF'QF^!6@?&C3(H]0W6.J6X(M=2@4&2,'^%@?OIGG:?P(R:^5=8_8?\>V-XR6
M%UI.I6V?EE$[1-C_ &E9>#]":_,\=DN(HU6Z,>:+VM^1^O9=Q!A<11BL1/EF
MM[[/S3/GFON+]ASP+<Z#X'U;Q#=QM$=:F1;=6')ABW /]"SN/^ @USGPR_8;
M-KJ$-[XWU."YAC(;^S--+%9/9Y" 0/4*.?[PKZSL[2#3[6&VMH4M[:%!''#&
MH544# 4 = !7KY+E-6C5^LUU:VRZ^IX?$&=4,11^J89\U]WTTZ+YDU%%%?:G
MYZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !4=Q<16D$DT\J0PQJ6>21@JJ!U))Z"LSQ9XJTWP3X;U#7=8N!:Z=8Q&6:
M0]<=@!W))  [D@5^;'QR_:*\1?&C5I4EFDT[PXC_ .C:3$^$P#PTN/OO[G@=
ML=_0P>"GBWIHEU/'S',Z67Q7-K)[+_,^X?$?[6'PM\,W#6\WBB&]G4X*Z=#)
M<K_WVBE#_P!]5%H'[7'PK\07"P)XF6QF8X U"WE@7\79=H_$U^9=%?0?V/0M
M;F=_E_D?(?ZR8KFORQM\_P#,_8^QOK;4K2*ZL[B*[M9EW1S0.'1U]0PX(^E3
MU^67P:^//B7X+ZPDVF7+76DNX-UI,SGR9AW('\#XZ,/09R.*_2SP#XZTKXD>
M$]/\0Z+-YMC>)N"MP\;#AD<=F4Y!_3CFO!QF!GA'=ZQ?4^MRW-*68)I*TENO
MU1T-%%%>:>T%%>,_'S]I+2_@W$NG6L*ZMXEF3>EH6Q' IZ/*1SSV4<GV&#7Q
M_P"(OVG?B5XBNGF?Q-<:>A.5@TX"!$'H-HW'\237A8S.<-@Y^S=Y2\NA]+@,
M@Q>/A[56C%[-]?1'Z345^=?@[]K3XB^%;N-KC5_[>LP?GM=30/N'M(,.#^./
M8U]J?!SXSZ+\9O#[7VF[K6^M\+>:?*P,D#'H<_Q*<'#=\'H016F"S;#XY\D-
M)=G^ACF&28K+H^TG9Q[K]3T"BBBO9/ "BBHYYX[6&2::18HHU+O)(0JJH&22
M3T % $E97B#Q7HOA.U^TZWJUCI%N>DE]<)"I]@6(R:^0?CQ^VY<M=7.B?#QU
MB@0F.779$#-(>A\E3P!_MD$GL!P3\E:UKFI>(]0DOM5O[G4KV0Y>XNY6ED;Z
MLQ)KWL/E-2HN:J^5?B?)XSB"C0DX4%SOOT_X)^E&J?M;?"C2I&23Q9%<.#C%
MK:SRC_OI4*_K6?'^V?\ ">1L-K]Q&/[S:=<8_1#7YYZ'X*\0^)ESH^@ZGJPS
MC-C9R3?^@J:VY/@G\0XTW-X%\2!?^P5/_P#$5W_V7A8Z2F[^J_R/(_M['S]Z
M%-6]'_F?HCI/[3GPMUI@MOXTT^,G_G\WVP_.55KT'1]>TSQ!:_:=+U&UU*W_
M .>UG.LJ?FI(K\C=6\)ZYH.?[3T;4-. Z_:[62+_ -" K8^$]GJ&J?$CPWIV
MF7ES8W-[J$%N9[25HG56<!B&4@C R?PK*IE%/E<H3_7_ ".BCQ%7YU"K25WV
MNOSN?K35>^O[;3;=I[NXAM8%(!EG<(HSTY/%6*\+_;4_Y-^UK_KYM?\ T<M?
M.T:?M:D:?=V/LL36^KT9U4K\J;^X]:_X37P]_P!![3/_  ,C_P#BJUX9H[B%
M)8G66*10R2(0592,@@CJ*_&ROUG^#O\ R2/P1_V ['_TG2O1QV!6$C&2E>YX
MV5YK+,9RBX<MEWN=?3681J68A5')). *=7Q1_P %#9'&L>"T#,$-O=$KG@_-
M'7%A:'UFJJ5[7/3QV*^I8>5?EO:VFV[L?7.H>/O#&E9%[XCTFS(Z_:+Z),?F
MU85U\>/AS:$B3QSX?)_Z9ZC$_P#Z"QK\I*LVNFW=]_Q[6LUQ_P!<HRW\A7T"
MR:FOBFSX]\2U7\-)?>S]2%_:)^&;-@>-]'S[W(%:NF_&+P)K#*EGXST&XD;I
M&NI0[_\ OG=FORO;PGKB+N;1M05?[QM7 _E67)&\,A1U9'7@JPP13_L>D_AF
M_P !?ZR8B/Q4E^)^R$,\=S$LL,BRQL,JZ$$'Z$5)7Y">&?&WB#P;<BXT+6K_
M $B7.2;.X:,-]0#@CV-?2OPE_;LUG2[B"P\=VJZO8DA3J=I&([F/W9!A7'T"
MGZ]*X:V45::O3?-^#/5PW$6'JOEK1Y/Q7]?(^YJ*S/#?B72_%^BVNKZ-?0ZC
MIMTN^*XA;*L/3U!'0@\@C!K3KPVFG9GU2DI*Z>@4444AA4-W>0:?;O<74\=M
M G+2S.%5><<D\"IJ^5?V^?'_ /9/@O2/"=O)B?5I_M-RJG_EA$1M!]C(5(_Z
MYFNC#T7B*L::ZG'C,2L'0E6ET_I'TA_PFOA[_H/:9_X&1_\ Q57M/U>QU='>
MPO;>]1#AFMY5D"GT.#Q7XZU]+?L)^/\ _A'?B==^')Y-MIKUOB,$\?:(@73\
MT,@]SMKV<1E/L:4JD97MY'S6$X@^L5X4IT[*6E[_ '=.Y^@%%%%?/'V(4444
M (2%&3P.YK!U+Q_X8T5F&H>)-(L2O47-]%'C_OIA7R[_ ,%#IY8].\#QK(RQ
MR27N]58@-@08R.]?%5>]A,L6(I*JYVOY'R689Y+!UY4(T[VMK?NK[6/U8N/C
M[\-[4D/XYT%O^N=_&_\ Z"34*?M$?#21L#QOHP/^U=*/YU^7MCX=U75$#6>F
M7EVIZ&"W=P?R%6Y? _B.!2TF@:I&O]YK*0#_ -!KM_LBBM'-_@>9_K%BGJJ2
M_$_5'2_BMX*UQU33_%VAWDC=(X=1A9OR#9KJ58,H92"I&01WK\;9H9+>1HY8
MVCD7@JX((_ UU'@SXJ>+OA[.DGA[Q#?::JG/D1REH6_WHFRC?B*SGDVG[N?W
MF]+B;6U6E]S_ $?^9^M=%?,'[/?[9%KX^O[7PYXPBATO7)B([:^A^6WNGZ!"
M#]QSVYP3P,' /T_7@5J%3#RY*BLSZ["XJCC*?M*+NOR"BBBN<ZPHHHH S]0\
M0Z7I,RQ7VI6=E*R[A'<3I&Q7)&<$].#^55?^$U\/?]![3/\ P,C_ /BJ_,_]
MH[Q__P +(^,7B#5(I/,L89OL5F0<CR8OE!'LQ#/_ ,#KS.OI:>3\T%*4[-^1
M\16XD]G4E"%.Z3WOO^!^RJL'4,I#*1D$=#2UX_\ LH^/_P#A8'P5T6663S+[
M3!_9ESDY.Z( (3[F,QG/J37L%?/U*;I3<);H^PH5HUZ4:L=FKA11161N%%%%
M !1110 4444 %%%% !115+6M8M?#VCWVJ7TGDV5E ]S/)_=1%+,?R!IK71";
M25V<]\2OBIX;^$V@G5?$=^+6-B5AMXQOFN&'\,:=S[]!GDBODOQ=_P %!-=N
M+IU\,^&K"RM0<+)JC//(P]=J,@4^V6^M?/\ \7/BCJGQ>\;7NOZD[!'8I:6N
M[*VT()VQK_,GN23WKBZ^PPN5TJ<4ZRO+\#\WQV?5ZLW'#OEC^+/J30/^"@'C
M"TNE_MC0-'U&US\RVOFV\F/9BSC_ ,=KZE^#O[0?A3XTVK+I,[VFK0KOGTN[
MPLR#NRX.'7/<=,C(&:_+:M/PWXCU'PCKMEK&D74EEJ-G()89HSRI'\P1D$'@
M@D&M,1E="I']VN5F.$SW%4)KVKYX];[_ "9^P=%<7\'OB-;_ !6^'>D>)(56
M*2ZCVW$*GB*93MD7Z;@2/8BNTKXR47"3C+='Z73J1JP4X.Z>I\;?\% O'T\7
M_".^#;>4I%*AU.[4'[XR4B!]LB0X]0/2OC*OH[]O*&6/XUVKR [)-(@:/Z"2
M4']0:^<:^[R^"AAH6ZZGY3G%253'5.;H[?<%%%%>@>,%?6?[ 7CZ:S\4:WX/
MGE)L[V#[?;HQX69"%<#_ 'D()_ZYBODRO=/V*X99?V@-%:/.R.VNFD_W?)8?
M^A%:X<=%3PTT^WY'JY74E3QM)QZNWWZ'Z150U[6(?#^AZCJEQ_Q[V-O)<R8_
MNHI8_H*OUSOQ&T>;Q!\/_$VEVP+7%[IEU;1@=V>)E _,BOSRHVH-QW/V*FHR
MG%2VN?E]XJ\2WWC'Q'J.MZE*9KV^F:>5L\ D\*/0 8 '8 5E4$%201@T5^*R
MDY-R>[/Z%C%0BHQ5D@KTG]G?QY<?#_XM:%=QR%;2\G6QO$S\KPR,%)/^Z=K?
M5:\VKHOASH\_B#Q]X<TVW4M+<ZA!&,=@9!D_0#)_"ML/*4*T)0W31SXJ$*E"
M<*GPM._W'ZK4445^T'\_!7QM^W#\<YK>0?#S1;@Q[D675Y8VP2",I!GT(PS>
MH*CU%?7'B+7+?PSX?U/6+LXM=/MI+J4_["*6/Z"OR.\4>(KSQ=XDU/6[]_,O
M=0N'N93VW,Q.![#.!["O=RG#JK4=26T?S/E.(,8Z%%48/6?Y?\'_ #*FFZ;=
M:QJ%M86,$EU>7,BPPP1+N:1V. H'<DFOOWX$_L<^'O ^GVVJ>+K6#7_$;@.;
M>8![6U/]U4/#L.[-D9Z =3Y9^P5\,(M7U_5?&U[")(M,_P!#L=PR//9<R./=
M4('_ &T]J^XZZ,SQLU/V%-VMN<F1Y93=-8JLKM[+]1D,,=O$D42+%&@VJB
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M*GB84>_](_.\/E[K8*KB>L;6^6_YGF7[!7C_ /L7Q]JGA6XDQ;ZS;^= I/\
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MXVT2_P!?AN+C1K6[CGN8;5%>214.[8 S*#D@ \C@FOM__AO[X>?] CQ+_P"
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MS?ABNRKEJ9Q44VH15COH\.494XNI)J5M=M_N/R^_X99^*O\ T)MY_P!_(O\
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M?BK_ -";>?\ ?R+_ .+H_P"&6?BK_P!";>?]_(O_ (NOU!HKSO[9K?RK\?\
M,]O_ %;PW\\OP_R/R^_X9:^*O_0FWG_?R+_XNN4\<?"_Q5\-6LU\3:-/I!O
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M0.#^!<-^E9D?[+?Q4D;:/!EZ#_M21 ?F7H^J9?+527_@0+,<XA[LH-_]N_\
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M *0K^X4?./Q45^D-%>%C,GPV,E[1^[+NOU/I,!GV+P$535I171]/1GY>:?\
M!/X@:G<"&#P7K@<G&9K"2)1]6< #\Z]T^%'[$>I7EU#?^.[A+"S4ACI=I*'F
MD]GD7Y5'^Z23ZKUK[/HKEP_#^%I2YJC<O78[<3Q1C*T.2FE#S6Y4TK2K/0]-
MMM/T^VBL[*V01PP0J%1%'0 5;HHKZ9))61\>VY.["BBBF(**** "BBB@ HHH
MH **** "BBOFWXW_ +4WB#X5_$"Z\/Z?X076+:&&*071>09+J"1\JD<4 ?25
M%?$R_P#!0#Q UQ]G'@BT-QG;Y0N9-V?3&W.:]/\ @/\ M.:]\7/'3:%J/A-=
M%MQ:27'VD/(?F4J OS*!SN_2@#Z*HHK@_CA\2)_A+\-=4\3VUE'J$UFT*BWE
M<HK;Y53J!VW9_"@#O**\I_9S^-%U\</!M_K5WID.E26U^UF(893(& CC?=D@
M<_/C\*Q/VE_VA[WX#-X<%GHUOJW]J_:-WGS-'Y?E>5C& <Y\P_E0![C17._#
MOQ1)XV\":!K\L"VLNIV45VT*,6"%U#;0>^,UT5 !17@W[2?[2%]\"=2T.UM-
M$M]6&HPRR,TTS1[-C*,# .?O5Y(G[>GBB1%=/ ,+(PR&6>4@CU^Y0!]J45X[
M^SG\<-4^-=CKD^IZ"NAMI\D2(JN[>9O#$GY@.FT?G7L5 !17"_&SXF/\(OAU
MJ/B=-/75'M7B06S3>4&WR*F=VT]-V>G.*^:]-_;8^(7B*WEO-&^'"W]C"Q62
M6VCN)U0@ D%U& <$'GUH ^SJ*^>/@7^V!I?Q6\0Q^'-6TIO#^MS;A;XF\V"=
M@"2N2 5; . <@XZYP#]#T %%%<)\;/BA%\'_ (=ZAXD>!;N>%HXK>U=]HFD=
M@ N?8;F/LIH [NBOF[]GS]K:7XR>.)/#FI:+;Z/(UJ\]M)#.TGF.A&4P0/X2
MS?\  37TC0 445Y'^T9\=)O@5X=TS4(-'35Y;^X:W"R7!B6/"[L\*<_3B@#U
MRBOC&W_;7^(=QIO]KQ_#A9=% +&\CBN#%M!P3YN-O&#^5>T? +]IK1OCD;FQ
M6RDT;7K6/SI+&202+)'D O&^!D D9! (R.O6@#V:BBN>^(?BB3P3X%U_7XH%
MNI=,L9KM878J'*(6VD]LXH Z&BOB>W_;^\17F[[/X'M9]OWO+N9&Q]<+71^
M_P!L_P 2>+O&V@Z'<>"([.#4;Z&UDN!+*?*5W"EN5QQG- 'UK1110 45\U>
M_P!K+4?&'QT'@&7P]:VUL;Z[M/MJW#%\0K*0VW&.?+'?O7L'QF^($WPM^&FM
M>*+>SCOYM/6(K;R.45]\J1\D#C&_/X4 =K17C_[-_P <[OXZ:!J^H7>E0Z4U
MC<K L<,ID# INR<@5[!0 45XE^T7\?-8^"MUH46E^'%UX:@DS2,SNOE;"@'W
M5/7<?RKQ*X_X* >(;27RY_!%I#)C.R2ZD4_D5H ^VJ*^3_A]^V1XF\9>.-"T
M.Y\#I8V^H7D=M)<B24^4K, 6Y7'&:^L* "BLOQ1J[>'_  SJ^J)&)GL;.:Y6
M-C@,40M@GWQ7B?[-_P"TS?\ QT\0:OIUWH=OI2V-JMPLD,[2%B7"X(('K0!]
M 4444 %%?,/Q9_;>TGPEKL^A^$])_P"$FOH9/)DNVE*6XDSC:@4%I.>,C ]"
M:Y_1_P!K?XI)J5BNK?#$I9W<\<*/]FNK4$NP4?O'##J?2@#Z^HHHH **^5/B
M)^VU):^++CP]X"\-'Q+<PR-%]JDWNLKKPWEQ1C<RC!^;(SZ8YJ;X<?M4^/-;
M\>:'X;\2_#TZ:=4N! L^R>U,8P2S[9%;=A03C(Z=: /J6BBB@ HHHH ****
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M_0TZM_WZB_PK1\._L(^'/#GB#3-6B\2ZI++8745TD;QQ[6*.& /'0XKZ<HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
